Contact
searchSearch
HMP Global

Volume 34 - Issue 3 - May / June 2026

Clinical Editor's Corner
What’s New in the “2026 Acute Pulmonary Embolism in Adults” Multi-Society Guidelines
05/28/2026
Morton J. Kern, MD, MSCAI, FACC, FAHA
New guidelines for the evaluation and management of acute pulmonary embolism (PE) in adults, a report of the American College of Cardiology (ACC) and American Heart Association (AHA) Joint Committee on clinical practice guidelines, are now...
New guidelines for the evaluation and management of acute pulmonary embolism (PE) in adults, a report of the American College of Cardiology (ACC) and American Heart Association (AHA) Joint Committee on clinical practice guidelines, are now...
New guidelines for the...
05/28/2026
Cath Lab Digest
Intravascular Imaging
Beyond Angiography: The Power of IVUS + NIRS in PCI
05/22/2026
Dhananjay Chatterjee, MD
"I work across multiple facilities, and we have access to the Makoto™ Intravascular Imaging System from Nipro Medical, which combines IVUS and near-infrared spectroscopy (NIRS), as well as IVUS platforms from Boston Scientific and Philips, in...
"I work across multiple facilities, and we have access to the Makoto™ Intravascular Imaging System from Nipro Medical, which combines IVUS and near-infrared spectroscopy (NIRS), as well as IVUS platforms from Boston Scientific and Philips, in...
"I work across multiple...
05/22/2026
Cath Lab Digest
Fem-Pop Intervention
Percutaneous Transmural Arterial Bypass for Complex Femoropopliteal Disease: A Case Series Across Challenging Anatomies
05/22/2026
Haris Umer Usman, MD, MS; Ramzan M. Zakir, MD
Drs. Usman and Zakir present 2 challenging cases that highlight how the DETOUR™ System (Endologix) was used for PTAB in complex femoropopliteal disease, including prior stenting, long-segment occlusion, and heavily calcified anatomy.
Drs. Usman and Zakir present 2 challenging cases that highlight how the DETOUR™ System (Endologix) was used for PTAB in complex femoropopliteal disease, including prior stenting, long-segment occlusion, and heavily calcified anatomy.
Drs. Usman and Zakir present 2...
05/22/2026
Cath Lab Digest
Peripheral Intervention
Thrombus Burden in ALI and the Role of the Rotarex™ Catheter System
05/22/2026
Jorge A. Miranda, MD; M. Laiq Raja, MD, FACC, FSCAI
The Rotarex™ Catheter System can help treat acute and subacute limb ischemia, in-stent restenosis, and mixed-morphology PAD lesions while supporting efficient, IVUS-guided revascularization.
The Rotarex™ Catheter System can help treat acute and subacute limb ischemia, in-stent restenosis, and mixed-morphology PAD lesions while supporting efficient, IVUS-guided revascularization.
The Rotarex™ Catheter System can...
05/22/2026
Cath Lab Digest
Intravascular Lithotripsy
The Aero Era: Early Experience With Shockwave C2 Aero
05/22/2026
Christopher L. Brown, MD
Christopher L. Brown, MD, describes his early experience with Shockwave C2 Aero plus a recent case, highlighting improved deliverability, better rewrap, and greater flexibility in treating complex calcified multivessel coronary disease.
Christopher L. Brown, MD, describes his early experience with Shockwave C2 Aero plus a recent case, highlighting improved deliverability, better rewrap, and greater flexibility in treating complex calcified multivessel coronary disease.
Christopher L. Brown, MD,...
05/22/2026
Cath Lab Digest
Clinical Trial Update
The ALL-RISE Trial: FFRangio and the Next Step in Coronary Physiology
05/19/2026
Ajay J. Kirtane, MD, SM
Ajay J. Kirtane, MD, SM, reviews the ALL-RISE trial and what FFRangio may mean for the future of coronary physiology.
Ajay J. Kirtane, MD, SM, reviews the ALL-RISE trial and what FFRangio may mean for the future of coronary physiology.
Ajay J. Kirtane, MD, SM, reviews...
05/19/2026
Cath Lab Digest
cath lab management
Building a Culture of Accountability: Using Registry Data to Engage Physicians and Drive Performance
05/19/2026
Carol Wesley, MSN, MHA, RN
In today’s rapidly evolving healthcare landscape, hospital executives face mounting pressure to deliver high-quality outcomes while maintaining financial sustainability. As reimbursement models shift toward value-based care and regulatory...
In today’s rapidly evolving healthcare landscape, hospital executives face mounting pressure to deliver high-quality outcomes while maintaining financial sustainability. As reimbursement models shift toward value-based care and regulatory...
In today’s rapidly evolving...
05/19/2026
Cath Lab Digest
Coronary Physiology Corner
Email Newsletter Alert – Coronary Physiology in One Place: Key Reads, Consensus Updates, and What to Watch Next
05/19/2026
Between new indices, evolving microvascular science, and a steady stream of CT- and angiography-derived tools, the evidence base for coronary physiology moves quickly. Much of it surfaces first in meeting halls and early online publications...
Between new indices, evolving microvascular science, and a steady stream of CT- and angiography-derived tools, the evidence base for coronary physiology moves quickly. Much of it surfaces first in meeting halls and early online publications...
Between new indices, evolving...
05/19/2026
Cath Lab Digest
Code Blue Training
Using High-Fidelity Simulation To Improve Teamwork and Clinical Metrics During Procedural Emergencies
03/20/2026
Belen Camacho, DNP, RN, NEA-BC, CV-BC, RCIS; Sally O. Gerard, DNP, RN, CDCES
Camacho and Gerard show that when cath lab–led teams rehearse rare, high-stakes procedural emergencies with high-fidelity code blue simulations, teamwork measurably improves and response times trend faster. They report earning strong staff...
Camacho and Gerard show that when cath lab–led teams rehearse rare, high-stakes procedural emergencies with high-fidelity code blue simulations, teamwork measurably improves and response times trend faster. They report earning strong staff...
Camacho and Gerard show that...
03/20/2026
Cath Lab Digest

Subscriber

Cath Lab Digest Newsletter

Clinical & Industry News

ASC 6,000 milestone procedures
Arizona Centers
Arizona-Based Tri-City Cardiology's ASC Surpasses 6,000 Procedures, Marking a Major Milestone in Outpatient Cardiovascular Care
05/29/2026
"Delivering more than 6,000 procedures in an outpatient environment speaks to the strength of our team, the sophistication of our facility, and our commitment to cardiovascular treatment," said Bruce Stec, ASC administrator at Tri-City...
"Delivering more than 6,000 procedures in an outpatient environment speaks to the strength of our team, the sophistication of our facility, and our commitment to cardiovascular treatment," said Bruce Stec, ASC administrator at Tri-City...
"Delivering more than 6,000...
05/29/2026
Cath Lab Digest
Awards
ACC President Roxana Mehran, MD, FACC, Receives Andreas Grüntzig Ethica Award
05/28/2026
The award, named after Andreas Grüntzig, the pioneering German cardiologist who developed the first balloon angioplasty, is the highest honor presented by the Percutaneous Cardiovascular Registry (PCR).
The award, named after Andreas Grüntzig, the pioneering German cardiologist who developed the first balloon angioplasty, is the highest honor presented by the Percutaneous Cardiovascular Registry (PCR).
The award, named after Andreas...
05/28/2026
Cath Lab Digest
Cancer and Heart Disease
CARDIOCARE Project Celebrates Major Advances in Protecting Heart Health of Older Patients With Breast Cancer at Risk of Cardiotoxicity From Cancer Treatment
05/28/2026
Key takeaways: Project combines a wide range of data from more than 2,200 breast cancer patients to help the development of personalised AI-driven tools. Researchers have developed two dedicated applications to monitor both physical...
Key takeaways: Project combines a wide range of data from more than 2,200 breast cancer patients to help the development of personalised AI-driven tools. Researchers have developed two dedicated applications to monitor both physical...
Key takeaways: Project...
05/28/2026
Cath Lab Digest
Radiation Protection Systems
Cathpax Rolls Out New Radiation Protection System Nova-X® Across EMEA Following Very Promising Clinical Results
05/28/2026
Cathpax has signed several distribution contracts in different geographic regions and is supplying Nova-X® to various neurointerventional centers.
Cathpax has signed several distribution contracts in different geographic regions and is supplying Nova-X® to various neurointerventional centers.
Cathpax has signed several...
05/28/2026
Cath Lab Digest
CTO Viability
Rentrop Collateral Grade as an Angiographic Predictor of Myocardial Viability in Chronic Total Occlusion
05/28/2026
Your heart already has its own built-in bypass system that predicts whether the heart muscle is alive or dead, according to new research from the University of East Anglia and Norfolk and Norwich University Hospital. A new study reveals...
Your heart already has its own built-in bypass system that predicts whether the heart muscle is alive or dead, according to new research from the University of East Anglia and Norfolk and Norwich University Hospital. A new study reveals...
Your heart already has its own...
05/28/2026
Cath Lab Digest
Vertex Catheter (Jupiter Endovascular)
Pulmonary Embolism
Jupiter Endovascular Announces Positive Results From SPIRARE II Pivotal Trial at EuroPCR 2026
05/26/2026
The Vertex system leverages the company’s patented Transforming Fixation (TFX) platform technology in a novel catheter system designed to navigate flexibly through the right heart and then stabilize on-demand in the pulmonary arteries for...
The Vertex system leverages the company’s patented Transforming Fixation (TFX) platform technology in a novel catheter system designed to navigate flexibly through the right heart and then stabilize on-demand in the pulmonary arteries for...
The Vertex system leverages the...
05/26/2026
Cath Lab Digest
Uncontrolled Hypertension
AstraZeneca's Baxfendy Approved in U.S. as Aldosterone Synthase Inhibitor Treatment for Adults With Hypertension
05/26/2026
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood...
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood...
...
05/26/2026
Cath Lab Digest
Gene-Editing Approaches
Single Dose of Lilly's PCSK9 Base Editor, VERVE-102, Reduced PCSK9 by up to 88% and LDL-C by up to 62%, With Durable Effects Supporting Potential as One-Time Hypercholesterolemia Treatment
05/26/2026
Eli Lilly and Company announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein...
Eli Lilly and Company announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein...
Eli Lilly and Company announced...
05/26/2026
Cath Lab Digest
Inflammation
Cardiometabolic Clinical Data Support Potential of NodThera's Ruvonoflast to Treat Inflammation at the Source
05/26/2026
Boston, MA –  NodThera, a clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiometabolic and neurologic diseases, announced the...
Boston, MA –  NodThera, a clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiometabolic and neurologic diseases, announced the...
Boston, MA –  NodThera, a...
05/26/2026
Cath Lab Digest
Intravascular Lithotripsy
AVS, Now Part of Stryker, Enrolls First Patient in First-in-Human Coronary Intravascular Lithotripsy Study
05/21/2026
BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
BOSTON--Amplitude Vascular...
05/21/2026
Cath Lab Digest

May 2026 Volume 34 Issue 3

View Issue Archive
Editorial Correspondence

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use